Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease

Movement Disorders

Volumn 19, Issue 5, 2004, Pages 554-560

  Fox, Susan ^a,f   Silverdale, Montague ^c   Kellett, Mark ^c   Davies, Rhys ^d   Steiger, Malcolm ^a   Fletcher, Nicholas ^a   Crossman, Alan ^b   Brotchie, Jonathan ^e  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c HOPE HOSPITAL   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Dyskinesia; Motor fluctuations; Naloxone; Opioids; Parkinson's disease

Indexed keywords

AMANTADINE; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; CABERGOLINE; ENTACAPONE; NALOXONE; OPIATE ANTAGONIST; OPIATE RECEPTOR; PERGOLIDE; PLACEBO; RECEPTOR SUBTYPE; ROPINIROLE; SELEGILINE; ANTIPARKINSON AGENT; LEVODOPA; NARCOTIC ANTAGONIST;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYANOSIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SELECTIVITY; DYSKINESIA; FEMALE; HUMAN; HYPOTENSION; LETHARGY; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; STATISTICAL SIGNIFICANCE; DOSE RESPONSE; FOLLOW UP; VIDEORECORDING;

ANTIPARKINSON AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FOLLOW-UP STUDIES; HUMANS; LEVODOPA; NALOXONE; NARCOTIC ANTAGONISTS; PARKINSON DISEASE; VIDEOTAPE RECORDING;

EID: 4544255049     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10693     Document Type: Article

References (48)

1. Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976;1:292-296.
2. Rajput AH, Fenton ME, Birdi S, et al. Clinical-pathological study of levodopa complications. Mov Disord 2002;17:289-296.
3. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia in Parkinson's disease: opportunities for novel treatments. Nat Rev Neurosci 2001;2:577-588.
4. Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induce dyskinesias in Parkinson's disease: implications for future strategies in treatment. Mov Disord 1990;5:100-108.
5. Cuello AC, Paxinos G. Evidence for a long Leu-enkephalin striatopallidal pathway in rat brain. Nature 1978;271:178-180.
6. Del Fiacco M, Paxinos G, Cuello AC. Neostriatal enkephalin-immunoreactive neurones project to the globus pallidus. Brain Res 1982;231:1-17.
7. Vincent SR, Hokfelt T, Christensson I, Terenius L. Immunohistochemical evidence for a dynorphinergic immunoreactive strionigral pathway. Eur J Pharmacol 1982;85:251-252.
8. Gerfen CG, Young WS III. Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridisation histochemistry and fluorescent retrograde tracing study. Brain Res 1988;460:161-167.
9. Seizinger BR, Grimm C, Hollt V, Herz A. Evidence for a selective processing of proenkephalin B into different opioid peptide forms in particular regions of rat brain and pituitary. J Neurochem 1984;42:447-457.
10. Breslin MB, Lindberg I, Benjannet S, Mathis JP, Lazure C, Seidah NG. Differential processing of proenkephalin by prohormone convertases 1(3) and 2 and furin. J Biol Chem 1993; 268:27084-27093.
11. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma F Jr, Sibley DR. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429-1432.
12. Engber TM, Susel Z, Kuo S, Gerfen CR, Chase TN. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res. 1991;552:113-118.
13. Henry B, Brotchie JM. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drugs Aging 1996;9:1-10.
14. Duty S, Brotchie JM. Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression. Exp Neurol 1997;144:423-432.
15. Andersson M, Hilbertson A, Cenci MA. Striatal fosB expression is causally linked with 1-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 1999;6:461-474
16. Cenci MA, Lee CS, Björklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998;10: 2694-2706.
17. Henry B, Crossman AR, Brotchie JM. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp Neurol 1999;155:204-220.
18. Jenner P. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann Neurol 2000;47(Suppl.):90-104.
19. Henry B, Duty S, Fox SH, Crossman AR, Brotchie JM. Increased striatal pre-proenkephalin B expression associated with dyskinesia in Parkinson's disease. Exp Neurol 2003;183:458-468.
20. Nisbet AP, Foster OJ, Kingsbury A, Eve DJ, Daniel SE, Marsden CD, Lees AJ. Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience 1995;66:361-376.
21. Calon F, Birdi S, Rajput AH, Hornykiewicz O, Bedard PJ, Di PT. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 2002;61:186-196.
22. Piccini P, Weeks RA, Brooks DJ. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesia. Ann Neurol 1997;42:720-726.
23. Henry B, Fox SH, Crossman AR, Brotchie JM. μ- and δ-Opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp Neurol 2001;171:139-146.
24. Klintenberg R, Svenningsson P, Gunne L, Andrén PE. Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism. J Neural Transm 2002;109:1295-1307.
25. Gomez-Mancilla B, Bedard PJ. Effect of nondopaminergic drugs on L-DOPA-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharm 1993;16:418-427.
26. Trabucchi M, Bassi S, Frattola L. Effects of naloxone on the "on-off" syndrome in patients receiving long-term levodopa therapy. Arch Neurol 1982;39:120-121.
27. Sandyk R, Snider SR. Naloxone treatment of L-dopa-induced dyskinesias in Parkinson's disease. Am J Psychiatry 1986;143:118.
28. Price P, Baxter RC, Parkes JD, Marsden CD. Opiate antagonists and Parkinson's disease. Arch Neurol 1979;36:661.
29. Nutt JG, Rosin AJ, Eisler T, Calne DB, Chase TN. Effect of an opiate antagonist on movement disorders. Arch Neurol 1978;35:810-811.
30. Rascol O, Fabre N, Blin O, et al. Naltrexone, an opiate antagonists, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord 1994;9:437-440.
31. Manson AJ, Katzenschlager R, Hobart J, Lees AJ. High dose naltrexone for dyskinesias induced by levodopa. J Neurol Neurosurg Psychiatry 2001;70:554-556.
32. Delitala G, Giusti M, Mazzocchi G, Granziera L, Tarditi W, Giordano G. Participation of endogenous opiates in regulation of the hypothalamic-pituitary-testicular axis in normal men. J Clin Endocrinol Metab 1983;57:1277-1281.
33. Bonuccelli U, Piccini P, Del Dotto P, Rossi G, Corsini GU, Muratorio A. Naloxone partly counteracts apomorphine side effects. Clin Neuropharmacol 1991;14:442-449.
34. Limone P, Calvelli P, Altare F, Ajmone-Catt P, Lima T, Molinatti GM. Evidence of an interaction between alpha-MSH and opioids in the regulation of gonadotropin secretion in man. J Endocrinol Invest 1997;20:207-210.
35. Coiro V, Volpi R, Capretti L, et al. Different effects of naloxone on the growth hormone response to melatonin and pyridostigmine in normal men. Metabolism 1998;47:814-816.
36. Tomasi PA, Fanciulli G, Palermo M, Pala A, Demontis MA, Delitala G. Opioid receptor blockade blunts growth hormone (GH) secretion induced by GH-releasing hormone in the male. Horm Metab Res 1998;30:34-36.
37. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55:181-184.
38. Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, Freeman T, Watts R. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992;7:2-13.
39. Evans JM, Hogg MI, Lunn JN, Rosen M. Degree and duration of reversal by naloxone of effects of morphine in conscious subjects. Br Med J 1974;2:589-591.
40. Berkowitz BA. The relationship of pharmokinetics to pharmacological activity, morphine, methadone and naloxone. Clin Pharmacokinet 1976;1:219-230.
41. Ngai SH, Berkowitz BA, Yang JC, Hempstead J, Spector S. Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. Anesthesiology 1976;44:398-401.
42. Manson AJ, Schrag A, Lees AJ. Low-dose olanzapine for levodopa induced dyskinesias. Neurology 2000;55:795-799.
43. Sieradzan KA, Fox SH, Hill M, Dick J, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 2001;57:2108-2111.
44. Rascol O, Nutt JG, Blin O, et al. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol 2001;58:249-254.
45. Rascol O, Arnulf I, Peyro-Saint Paul H, et al. Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord 2001;16:708-713.
46. Verhagen Metman L, Del Dotto P, Natté R, van den Munckhof P, Chase TN. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 1998;51:203-206.
47. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-1326.
48. Strong JA, Dalvi A, Samaha FJ, Gong J, Xu K, Yue X, Yu L. Mu opioid receptor polymorphisms and L-Dopa induced dyskinesia in Parkinson's disease. Proc Soc Neurosci 1999;25:846.2.